Halozyme Therapeutics (HALO) 8.74 $HALO
Halozyme Therapeutics (HALO) Stock Is Slipping Today on Weak Third Quarter Earnings
at The Street - Tue Nov 11, 10:42AM CST
Halozyme Therapeutics (HALO) stock is down after the company reported lower than expected third quarter earnings late Monday.
HALO: 8.74 (-0.24)
Halozyme net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 7:55AM CST
HALO: 8.74 (-0.24)
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:33PM CST
HALO: 8.74 (-0.24)
Halozyme Therapeutics meets 3Q profit forecasts
Automated Insights - Mon Nov 10, 5:51PM CST
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Monday reported a loss of $20.3 million in its third quarter.
HALO: 8.74 (-0.24)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:36PM CST
DTSI: 32.81 (-0.68), W: 22.01 (+0.70), HALO: 8.74 (-0.24), MODN: 10.24 (-0.26), CALL: 8.34 (-0.34), LLNW: 2.69 (unch), KRG: 26.74 (-0.06), VSLR: 11.70 (-0.63), CMLS: 3.33 (-0.02), SSE: 11.19 (-0.54)
Halozyme Therapeutics misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:21PM CST
HALO: 8.74 (-0.24)
Halozyme Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 10, 3:05PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter ended September 30, 2014. Financial highlights for the third quarter include revenues of $14.6 million and a net loss of $20.3 million, or $0.16 per share. This compares to revenues of $16.0 million and a net loss of $19.3 million, or $0.17 per share, for the third quarter of 2013.
HALO: 8.74 (-0.24)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:35PM CST
HK: 3.04 (-0.01), WWD: 50.13 (-1.10), LLNW: 2.69 (unch), FXEN: 2.58 (-0.11), RMTI: 11.01 (-0.23), CZR: 16.51 (+2.84), EGY: 7.01 (-0.02), ICUI: 84.95 (+0.22), ICEL: 7.64 (-0.03), SAAS: 8.81 (+0.01), DMD: 5.34 (-0.36), NPSP: 29.78 (+0.61), SCLN: 8.66 (-0.01), ATHX: 1.39 (-0.04), CMLS: 3.33 (-0.02), TC: 1.93 (-0.12), ATW: 35.12 (-0.40), CLUB: 5.78 (-0.19), RAX: 43.33 (+0.73), PTLA: 26.67 (-1.07), IPAR: 28.22 (-0.63), ATLS: 36.18 (-0.59), AMBC: 26.22 (-0.27), CUI: 7.06 (-0.71), PDLI: 7.89 (-0.13), OMER: 19.57 (-0.14), PRAA: 62.10 (-0.23), CARA: 8.06 (-0.02), HALO: 8.74 (-0.24), MODN: 10.24 (-0.26), CALL: 8.34 (-0.34), ASEI: 44.31 (-0.46), HGR: 21.24 (+0.53), ERII: 4.69 (-0.14)
Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
PR Newswire - Wed Nov 05, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday, November 12, 2014 at 4:00 p.m. ET/2:00 p.m. MT/1:00 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
HALO: 8.74 (-0.24)
Halozyme to Host Third Quarter 2014 Financial Results Conference Call
PR Newswire - Mon Nov 03, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2014 on Monday, November 10, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the third quarter 2014.
HALO: 8.74 (-0.24)
Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma
PR Newswire - Fri Oct 31, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 30, 2014, the NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow Jones Industrial Average advanced 1.30%, to finish the day at 17,195.42, and the S&P 500 closed at 1,994.65, up 0.62%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index also advancing 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
SNTA: 3.23 (-0.13), ACAD: 27.90 (+0.63), HALO: 8.74 (-0.24), ISIS: 50.71 (-0.37), NSPH: 0.43 (-0.01)
NewLink Genetics Corporation (NLNK) in Focus: Stock Soars 15.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 8:18AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as the company saw its shares rise by over 15% on the day.
HALO: 8.74 (-0.24), NLNK: 31.00 (-1.39), ILMN: 185.00 (-1.92), EXAS: 23.11 (+0.61)
Vertex Pharmaceuticals' Kalydeco Wins FDA Panel Backing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 4:54PM CDT
Vertex Pharmaceuticals Inc.'s (VRTX) Kaydeco got favorable vote from PADAC for the treatment of 6 year old and above cystic fibrosis patients with R117H mutation.
MDVN: 107.21 (+0.88), VRTX: 112.72 (-3.96), HALO: 8.74 (-0.24), LGND: 57.96 (+0.26)
Biogen's Q3 Earnings Top Estimates, View Raised Again - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 22, 12:10PM CDT
Biogen (BIIB) raised its earnings guidance for 2014 once again.
MDVN: 107.21 (+0.88), BIIB: 317.98 (-3.04), HALO: 8.74 (-0.24), LGND: 57.96 (+0.26)
Actelion Misses Q3 Earnings Expectation, Ups 2014 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 10:40AM CDT
Actelion Ltd. (ALIOF) reported third-quarter earnings of $1.36 per American Depository Receipt (ADR), but below the Zacks Consensus Estimate of $1.50 per share.
MDVN: 107.21 (+0.88), HALO: 8.74 (-0.24), LGND: 57.96 (+0.26)
Orexigen (OREX) Shows Strength: Stock Gains 11.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 8:25AM CDT
Orexigen (OREX) was a big mover last session, with shares rising over 11% on the day.
MDVN: 107.21 (+0.88), OREX: 5.86 (+0.02), HALO: 8.74 (-0.24), LGND: 57.96 (+0.26)
Illumina (ILMN) Looks Strong: Stock Gains 9.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 7:44AM CDT
Illumina (ILMN) was a big mover last session, as the company saw its shares jump over 9% on the day
MACK: 8.39 (-0.16), MDVN: 107.21 (+0.88), HALO: 8.74 (-0.24), ILMN: 185.00 (-1.92)
NewLink-Roche Ink Deal for Oncology Candidate Development - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 5:05PM CDT
NewLink Genetics Corporation (NLNK) has signed an exclusive license agreement with Roche for the development of its oncology candidate, NLG919.
MDVN: 107.21 (+0.88), HALO: 8.74 (-0.24), NLNK: 31.00 (-1.39)
Illumina (ILMN) Tops Q3 Earnings, Revenues; Ups Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:40AM CDT
Illumina Inc.(ILMN) reported adjusted earnings of 77 cents per share in the third quarter of 2014, beating the Zacks Consensus Estimate by 37.5%.
MACK: 8.39 (-0.16), MDVN: 107.21 (+0.88), HALO: 8.74 (-0.24), ILMN: 185.00 (-1.92)
Vital Therapies (VTL) in Focus: Stock Adds 7.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:39AM CDT
Vital Therapies, Inc. (VTL) was a big mover last session, as its shares rose almost 8% on the day.
MACK: 8.39 (-0.16), HALO: 8.74 (-0.24), VTL: 17.82 (-0.04), ILMN: 185.00 (-1.92)
Halozyme Therapeutics (HALO) Stock Is Slipping Today on Weak Third Quarter Earnings
at The Street - Tue Nov 11, 10:42AM CST
Halozyme Therapeutics (HALO) stock is down after the company reported lower than expected third quarter earnings late Monday.
HALO: 8.74 (-0.24)
Halozyme net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 7:55AM CST
HALO: 8.74 (-0.24)
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:33PM CST
HALO: 8.74 (-0.24)
Halozyme Therapeutics meets 3Q profit forecasts
Automated Insights - Mon Nov 10, 5:51PM CST
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Monday reported a loss of $20.3 million in its third quarter.
HALO: 8.74 (-0.24)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:36PM CST
DTSI: 32.81 (-0.68), W: 22.01 (+0.70), HALO: 8.74 (-0.24), MODN: 10.24 (-0.26), CALL: 8.34 (-0.34), LLNW: 2.69 (unch), KRG: 26.74 (-0.06), VSLR: 11.70 (-0.63), CMLS: 3.33 (-0.02), SSE: 11.19 (-0.54)
Halozyme Therapeutics misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:21PM CST
HALO: 8.74 (-0.24)
Halozyme Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 10, 3:05PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter ended September 30, 2014. Financial highlights for the third quarter include revenues of $14.6 million and a net loss of $20.3 million, or $0.16 per share. This compares to revenues of $16.0 million and a net loss of $19.3 million, or $0.17 per share, for the third quarter of 2013.
HALO: 8.74 (-0.24)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:35PM CST
HK: 3.04 (-0.01), WWD: 50.13 (-1.10), LLNW: 2.69 (unch), FXEN: 2.58 (-0.11), RMTI: 11.01 (-0.23), CZR: 16.51 (+2.84), EGY: 7.01 (-0.02), ICUI: 84.95 (+0.22), ICEL: 7.64 (-0.03), SAAS: 8.81 (+0.01), DMD: 5.34 (-0.36), NPSP: 29.78 (+0.61), SCLN: 8.66 (-0.01), ATHX: 1.39 (-0.04), CMLS: 3.33 (-0.02), TC: 1.93 (-0.12), ATW: 35.12 (-0.40), CLUB: 5.78 (-0.19), RAX: 43.33 (+0.73), PTLA: 26.67 (-1.07), IPAR: 28.22 (-0.63), ATLS: 36.18 (-0.59), AMBC: 26.22 (-0.27), CUI: 7.06 (-0.71), PDLI: 7.89 (-0.13), OMER: 19.57 (-0.14), PRAA: 62.10 (-0.23), CARA: 8.06 (-0.02), HALO: 8.74 (-0.24), MODN: 10.24 (-0.26), CALL: 8.34 (-0.34), ASEI: 44.31 (-0.46), HGR: 21.24 (+0.53), ERII: 4.69 (-0.14)
Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
PR Newswire - Wed Nov 05, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday, November 12, 2014 at 4:00 p.m. ET/2:00 p.m. MT/1:00 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
HALO: 8.74 (-0.24)
Halozyme to Host Third Quarter 2014 Financial Results Conference Call
PR Newswire - Mon Nov 03, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2014 on Monday, November 10, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the third quarter 2014.
HALO: 8.74 (-0.24)
Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma
PR Newswire - Fri Oct 31, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 30, 2014, the NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow Jones Industrial Average advanced 1.30%, to finish the day at 17,195.42, and the S&P 500 closed at 1,994.65, up 0.62%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index also advancing 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
SNTA: 3.23 (-0.13), ACAD: 27.90 (+0.63), HALO: 8.74 (-0.24), ISIS: 50.71 (-0.37), NSPH: 0.43 (-0.01)
NewLink Genetics Corporation (NLNK) in Focus: Stock Soars 15.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 8:18AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as the company saw its shares rise by over 15% on the day.
HALO: 8.74 (-0.24), NLNK: 31.00 (-1.39), ILMN: 185.00 (-1.92), EXAS: 23.11 (+0.61)
Vertex Pharmaceuticals' Kalydeco Wins FDA Panel Backing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 4:54PM CDT
Vertex Pharmaceuticals Inc.'s (VRTX) Kaydeco got favorable vote from PADAC for the treatment of 6 year old and above cystic fibrosis patients with R117H mutation.
MDVN: 107.21 (+0.88), VRTX: 112.72 (-3.96), HALO: 8.74 (-0.24), LGND: 57.96 (+0.26)
Biogen's Q3 Earnings Top Estimates, View Raised Again - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 22, 12:10PM CDT
Biogen (BIIB) raised its earnings guidance for 2014 once again.
MDVN: 107.21 (+0.88), BIIB: 317.98 (-3.04), HALO: 8.74 (-0.24), LGND: 57.96 (+0.26)
Actelion Misses Q3 Earnings Expectation, Ups 2014 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 10:40AM CDT
Actelion Ltd. (ALIOF) reported third-quarter earnings of $1.36 per American Depository Receipt (ADR), but below the Zacks Consensus Estimate of $1.50 per share.
MDVN: 107.21 (+0.88), HALO: 8.74 (-0.24), LGND: 57.96 (+0.26)
Orexigen (OREX) Shows Strength: Stock Gains 11.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 8:25AM CDT
Orexigen (OREX) was a big mover last session, with shares rising over 11% on the day.
MDVN: 107.21 (+0.88), OREX: 5.86 (+0.02), HALO: 8.74 (-0.24), LGND: 57.96 (+0.26)
Illumina (ILMN) Looks Strong: Stock Gains 9.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 7:44AM CDT
Illumina (ILMN) was a big mover last session, as the company saw its shares jump over 9% on the day
MACK: 8.39 (-0.16), MDVN: 107.21 (+0.88), HALO: 8.74 (-0.24), ILMN: 185.00 (-1.92)
NewLink-Roche Ink Deal for Oncology Candidate Development - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 5:05PM CDT
NewLink Genetics Corporation (NLNK) has signed an exclusive license agreement with Roche for the development of its oncology candidate, NLG919.
MDVN: 107.21 (+0.88), HALO: 8.74 (-0.24), NLNK: 31.00 (-1.39)
Illumina (ILMN) Tops Q3 Earnings, Revenues; Ups Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:40AM CDT
Illumina Inc.(ILMN) reported adjusted earnings of 77 cents per share in the third quarter of 2014, beating the Zacks Consensus Estimate by 37.5%.
MACK: 8.39 (-0.16), MDVN: 107.21 (+0.88), HALO: 8.74 (-0.24), ILMN: 185.00 (-1.92)
Vital Therapies (VTL) in Focus: Stock Adds 7.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:39AM CDT
Vital Therapies, Inc. (VTL) was a big mover last session, as its shares rose almost 8% on the day.
MACK: 8.39 (-0.16), HALO: 8.74 (-0.24), VTL: 17.82 (-0.04), ILMN: 185.00 (-1.92)
